Revance Announces Pricing of Public Offering of Common Stock

NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions (“Revance” or the “Company”), today announced
the pricing of an underwritten public offering of 5,882,353 shares of
its common stock at a price to the public of $17.00 per share. Revance
has granted the underwriters a 30-day option to purchase up to an
aggregate of additional 882,352 shares from the Company. The gross
proceeds to the Company from the offering, excluding any exercise by the
underwriters of their 30-day option to purchase additional shares, are
expected to be approximately $100 million before deducting underwriting
discounts and commissions and other estimated offering expenses payable
by the Company. The offering is expected to close on or about January
22, 2019, subject to customary closing conditions. The Company intends
to use the net proceeds received from its offering of common stock for
working capital and general corporate purposes, including clinical trial
and related expenses, research and development expenses, general and
administrative expenses, and capital investments.

Goldman Sachs & Co. LLC, Cowen and Piper Jaffray are acting as
book-running managers and Guggenheim Securities is acting as lead
manager.

The securities described above are being offered by Revance pursuant to
an automatic shelf registration statement previously filed with the
Securities and Exchange Commission on December 5, 2017. The offering
will be made only by means of a prospectus supplement. When available,
copies of the prospectus supplement and accompanying prospectus relating
to the proposed public offering may be obtained by contacting Goldman
Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com;
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or
by emailing PostSaleManualRequests@broadridge.com;
or Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by
email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About Revance Therapeutics, Inc.

Revance is a clinical-stage biotechnology company focused on the
development, manufacturing, and commercialization of novel
neuromodulators for multiple aesthetic and therapeutic indications.
Revance is leveraging its proprietary portfolio of botulinum toxin type
A compounds, formulated with its patented and proprietary peptide
excipient technology, to address unmet needs in large and growing
neuromodulator markets.

“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward
looking, such as those, among others, relating to Revance’s expectations
regarding the completion of the proposed public offering. Actual results
or developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties related
to whether or not Revance will be able to raise capital through the sale
of shares of common stock, the final terms of the proposed offering,
market and other conditions, the satisfaction of customary closing
conditions related to the proposed public offering and the impact of
general economic, industry or political conditions in the United States
or internationally. There can be no assurance that Revance will be able
to complete the proposed public offering on the anticipated terms, or at
all. Revance will need to raise additional capital to fund its
operations and may be unable to raise capital when needed, which would
force Revance to delay, reduce or eliminate its product development
programs or commercialization efforts. You should not place undue
reliance on these forward-looking statements, which apply only as of the
date of this press release. Additional risks and uncertainties relating
to the proposed offering, Revance and its business can be found under
the heading “Risk Factors” in the prospectus supplement (and documents
incorporated by reference therein) related to the proposed public
offering filed with the Securities and Exchange Commission. Revance
expressly disclaims any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained
herein to reflect any change in its expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.

Contacts

INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
John Grimaldi, 212-213-0006
jgrimaldi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com